PWMG
VNDA icon

Prestige Wealth Management Group’s Vanda Pharmaceuticals VNDA Stock Holding History

Prestige Wealth Management Group’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-53
Closed -$392 – 1159
2022
Q4 		$392 Hold
53
– – ﹤0.01% 1096
2022
Q3 		$1K Buy
+53
New +$560 ﹤0.01% 933

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Prestige Wealth Management Group's VNDA Position: Q1 2023 in Review

Prestige Wealth Management Group sold out of Vanda Pharmaceuticals (VNDA) in Q1 2023, closing a stake of 53 shares — an estimated $392 sold.

Prestige Wealth Management Group first reported a position in VNDA in Q3 2022 and held it in 2 quarters. The position peaked at $1K in Q3 2022. 177 funds tracked by Wall St. Rank hold VNDA as of Q1 2023.

  • Prestige Wealth Management Group reported no remaining Vanda Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Prestige Wealth Management Group sold 53 Vanda Pharmaceuticals shares in Q1 2023, an estimated $392.
  • Prestige Wealth Management Group first reported a position in Vanda Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Prestige Wealth Management Group's Vanda Pharmaceuticals position peaked at $1K in Q3 2022.
  • 177 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2023.

Based on Prestige Wealth Management Group's 13F filing for Q1 2023, filed 16 May 2023.